Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis

Inflammation Research

Volumn 56, Issue 11, 2007, Pages 439-446

  Masunaga, Y ^a   Noto, T ^a   Suzuki, K ^a   Takahashi, K ^a   Shimizu, Y ^a   Morokata, T ^a  

^a Pharmacology Research Laboratories   (Japan)

Author keywords

Chemokine; Colitis; Cytokine; IBD; MDR1a mice

Indexed keywords

CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL STIMULATION; COLITIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATORY INFILTRATE; LARGE INTESTINE; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TH1 CELL; UPREGULATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHEMOKINES; COLITIS; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; INTESTINE, LARGE; LYMPH NODES; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS;

EID: 38549166392     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-6078-6     Document Type: Article

References (43)

1. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
2. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
3. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359: 1661-5.
4. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26-33.
5. Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 2004; 5: 530-9.
6. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003; 73: 1282-92.
7. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-5.
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
9. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-31.
10. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997; 160: 161-75.
11. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028-33.
12. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990; 10: 1652-63.
13. Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002; 160; 739-51.
14. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733-44.
15. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-8.
16. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-7.
17. Salmi M, Jalkanen S. Molecules controlling lymphocyte migration to the gut. Gut 1999; 45: 148-53.
18. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12: 336-41.
19. Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 2004; 4: 83-9.
20. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
21. Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol 2004; 143: 590-8.
22. Jacobson K, McHugh K, Collins SM. The mechanism of altered neural function in a rat model of acute colitis. Gastroenterology 1997; 112: 156-62.
23. Iwai A, Iwashita E. Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig Dis Sci 1998; 43(9 Suppl): 143S-147S.
24. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice. Am J Physiol Gastrointest Liver Physiol. 2005; 289: G153-62.
25. Arai Y, Takanashi H, Kitagawa H, Okayasu I. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998; 10: 890-6.
26. Morteau O, More J, Pons L, Bueno L. Platelet-activating factor and interleukin 1 are involved in colonic dysmotility in experimental colitis in rats. Gastroenterology 1993; 104: 47-56.
27. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005; 307: 734-8.
28. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52.
29. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587-95.
30. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990; 31: 686-9.
31. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50-4.
32. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989; 30: 835-8.
33. Street ME, de'Angelis G, Camacho-Hubner C, Giovannelli G, Ziveri MA, Bacchini PL et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004; 61: 159-64.
34. Nemetz A, Nosti-Escanilla MP, Molnar T, Kope A, Kovacs A, Feher J et al. IL1β gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999; 49: 527-31.
35. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003; 199: 28-35.
36. Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U et al. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch 2002; 441: 500-13.
37. Grimm MC, Elsbury SK, Pavli P, Doe WF. Interleukin 8: cells of origin in inflammatory bowel disease. Gut 1996 ;38: 90-8.
38. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 1999; 94: 704-12.
39. Daig R, Andus T, Aschenbrenner E, Falk W, Scholmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996; 38: 216-22.
40. Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, Dawson T et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000; 164: 6303-12.
41. Ajuebor MN, Kunkel SL, Hogaboam CM. The role of CCL3/macrophage inflammatory protein-1alpha in experimental colitis. Eur J Pharmacol 2004; 497: 343-9.
42. Ajuebor MN, Zagorski J, Kunkel SL, Strieter RM, Hogaboam CM. Contrasting roles for CXCR2 during experimental colitis. Exp Mol Pathol 2004; 76: 1-8.
43. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 2001; 166: 552-8.